| |
|
|
|
|
|
|
|||
|
Blood, 1 June 2007, Vol. 109, No. 11, pp. 4973-4979. Prepublished online as a Blood First Edition Paper on February 6, 2007; DOI 10.1182/blood-2006-11-054916.
Submitted November 6, 2006
The Leukemia Laboratory, Dept of Hematology, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark * Corresponding author; email: par.josefsson{at}pc.dk.
We recently identified a disease-specific gene CLLU1 in chronic lymphocytic leukemia (CLL), and also demonstrated that high CLLU1 expression levels predict poor clinical outcome. To validate this finding, we measured CLLU1 mRNA expression levels by real-time RT-PCR in 175 patients with CLL. Analyses of IgVH mutational status, ZAP-70 expression, CD38 expression and chromosomal aberrations were also performed. High levels of CLLU1 expression were associated with shorter overall survival (P = 0.0016), with a 7 % increase in risk of early death by each doubling of the CLLU1 expression level. Stratification for age at diagnosis demonstrated a strong prognostic significance of CLLU1 expression in patients younger than 70 years (P < 0.0001), but not in patients aged 70 or more (P = 0.61). The prognostic significance of IgVH mutational status and ZAP-70 expression had a similar age-dependent variation. Multivariate analysis in the younger age group showed that CLLU1 expression analysis added further prognostic information within all prognostic subgroups, with the exception of unmutated IgVH CLL patients. Only CLLU1 expression and IgVH mutational status had independent predictive power. Thus analysis of CLLU1 expression is highly applicable in risk prediction in CLL for patients of an age eligible for risk stratification.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||